Endothelial and Neuronal Nitric Oxide Activate Distinct Pathways on Sympathetic Neurotransmission in Rat Tail and Mesenteric Arteries

Joana Beatriz Sousa1,2*, Maria Sofia Vieira-Rocha1,2, Silvia M. Arribas3, María Carmen González3, Paula Fresco1, Carmen Diniz1,2

1 Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal, 2 LAQV/REQUIMTE, University of Porto, Porto, Portugal, 3 Department of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

* joanabeatrizsousa@gmail.com

Abstract

Nitric oxide (NO) seems to contribute to vascular homeostasis regulating neurotransmission. This work aimed at assessing the influence of NO from different sources and respective intracellular pathways on sympathetic neurotransmission, in two vascular beds. Electrically-evoked [3H]-noradrenaline release was assessed in rat mesenteric and tail arteries in the presence of NO donors or endothelial/neuronal nitric oxide synthase (NOS) inhibitors. The influence of NO on adenosine-mediated effects was also studied using selective antagonists for adenosine receptors subtypes. Location of neuronal NOS (nNOS) was investigated by immunohistochemistry (with specific antibodies for nNOS and for Schwann cells) and Confocal Microscopy. Results indicated that: 1) in mesenteric arteries, noradrenaline release was reduced by NO donors and it was increased by nNOS inhibitors; the effect of NO donors was only abolished by the adenosine A1 receptors antagonist; 2) in tail arteries, noradrenaline release was increased by NO donors and it was reduced by eNOS inhibitors; adenosine receptors antagonists were devoid of effect; 3) confocal microscopy showed nNOS staining in adventitial cells, some co-localized with Schwann cells. nNOS staining and its co-localization with Schwann cells were significantly lower in tail compared to mesenteric arteries. In conclusion, in mesenteric arteries, nNOS, mainly located in Schwann cells, seems to be the main source of NO influencing perivascular sympathetic neurotransmission with an inhibitory effect, mediated by adenosine A1 receptors activation. Instead, in tail arteries endothelial NO seems to play a more relevant role and has a facilitatory effect, independent of adenosine receptors activation.
Introduction

Nitric oxide (NO) contributes to vascular homeostasis [1–3] by modulating the vascular dilator tone and regulating local cell growth. Since NO is an uncharged and highly soluble molecule in hydrophobic environments, it can freely diffuse across biological membranes and signal on vascular cells distant from its site of generation [4]. Therefore, NO can modify vascular smooth muscle tone directly, acting on smooth muscle cells, or indirectly, by modulating sympathetic neurotransmission. In fact, there is evidence demonstrating the influence of NO on sympathetic neurotransmission in various vascular beds, such as mesenteric artery [5–12], pulmonary artery [13–15], heart and coronary arteries [12,16]. There are conflicting data concerning the influence exerted by NO on noradrenaline release: some authors claim that NO inhibits [17,18] whereas other studies showed an increase in noradrenaline release caused by NO [19–21]. However, most of these studies have been performed in heart, brain or urethra and, therefore, information on the direct influence of NO on perivascular sympathetic transmission is not fully understood.

It is conceivable that NO mediated-effects, in addition to the classically accepted activation of intracellular cGMP-dependent pathways [19] can also be related to cGMP-independent pathways, namely by inducing a decrease in mitochondrial respiration, with subsequent adenosine accumulation [22]. Therefore, it is possible that adenosine and its receptors (adenosine receptors) might participate on the modulation of sympathetic neurotransmission exerted by NO. It is worth noting that we have previously demonstrated that adenosine receptors are present in perivascular sympathetic nerves modulating noradrenaline release in mesenteric [23–25] and tail arteries [26–30].

This work aimed to clarify the NO influence on perivascular sympathetic neurotransmission (noradrenaline release), assessing: 1) the source of vascular NO, 2) the intracellular pathways implicated and 3) the potential role of adenosine or its receptors. For this purpose, in the present study, two different vessels were used, mesenteric and tail arteries, which have been extensively used as models for the study of neuromodulation exerted by many substances in the vasculature [5,7,8,31–33] and where we have previously described the presence of adenosine receptors on sympathetic nerves [24,27].

Materials and Methods

Handling and care of animals were conducted according to the European guidelines (Directive 2010/63/EU) on the protection of animals used for scientific purposes in agreement with the NIH guidelines. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Porto (Permit Number: 13/11/2013).

Animals and arterial tissue

Adult male Wistar Kyoto rats (12 weeks old, 270–350 g; Charles River, Barcelona, Spain) were used. Animals were sacrificed using guillotine. Seven arterial segments (5 to 9 mg) were obtained from each tail artery and four arterial segments (4–7 mg) were obtained from each mesenteric artery. Two animals per experiment were used. For each condition, results obtained from 5 to 24 tissue segments were analyzed.

Chemicals

The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); Desipramine hydrochloride, Sodium
Nitroprusside (SNP), Diethylamine NONOate diethylammonium salt (DEA-NONOate), Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME), Nω-Propyl-L-arginine hydrochloride and L-NIO dihydrochloride, desipramine hydrochloride, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine (SCH 58261), 5-Iodotubericidin (ITU) and Triton X-100 were purchased from Sigma-Aldrich (Sinha, Portugal). The following antibodies were used: mouse monoclonal anti-NOS1 (sc-5302), were purchased from Santa Cruz Biotechnology, Inc., CA, USA; rabbit GFAP polyclonal antibody (18-0063) was purchased from Invitrogen, Life Technologies, SA, Madrid, Spain). The following fluorescent probes were used: Alexa Fluor 488 goat anti-mouse IgG (H +L) antibody, highly cross-adsorbed and Alexa Fluor 647 goat anti-rabbit IgG (H+L) antibody, highly cross-adsorbed (Molecular Probes) secondary fluorescent antibodies (Invitrogen, Life Technologies, SA, Madrid, Spain); vectashield mounting medium with DAPI (Vector Laboratories, UK). Stock solutions were made up in dimethylsulphoxide (DMSO: 0.01% v/v, final concentration) or distilled water and diluted in superfusion medium immediately before use. DMSO was added to the superfusion medium (final concentration 0.01%), in parallel control experiments.

[^3H]-Noradrenaline release experiments
[^3H]-noradrenaline release experiments were carried out as previously described [23,24,27–29]. Briefly, the arterial segments were pre-incubated in 2 ml Krebs-Henseleit solution containing 0.1 μmol/L[^3H]-noradrenaline (for 60 min at 37°C) and transferred to superfusion chambers, superfused with[^3H]-noradrenaline-free medium (1 ml.min⁻¹; constant rate: Krebs-Henseleit solution with desipramine 400 nmol/L to inhibit noradrenaline’s neuronal uptake). Up to three periods of electrical stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo Sachs Elektronik, March-Hugstetten, Germany): two stimulation periods (S₁ and S₂) were applied with 30 min intervals, t = 90 min and t = 120 min, respectively. The superfusate was collected each 5 min period from 85 min of superfusion onwards. At the end of the experiments (t = 130 min), tritium was measured in superfusate samples and solubilized arteries (sonicated for 1h with 2.5 ml perchloric acid (0.2 mol/L)) by liquid scintillation spectrometry (LS 6500, Beckman Instruments, Fullerton, USA) after adding 6 ml of a scintillation mixture (Optiphase 'Hisafe' 3, PerkinElmer, I.L.C., Lisboa, Portugal) to each sample. Tissue labelling with[^3H]-noradrenaline and evaluation of electrically-evoked tritium overflow changes was performed as previously described [23,24].

To study the effects of NO from different sources, experiments were performed in the presence or absence of NOS inhibitors (Nω-Nitro-L-arginine methyl ester hydrochloride, Nω-Propyl-L-arginine hydrochloride and L-NIO dihydrochloride) and donors (SNP and DEA-NONOate), adenosine receptors antagonists (DPCPX and SCH 58621) or the adenosine kinase inhibitor (ITU), which were added after S₁ and kept until the end of the experiment.

Laser scanning confocal microscopy (LSCM) experiments
Immunohistochemistry procedures were performed as previously described [24]. From each artery four segments were obtained, immediately placed in cold phosphate buffer solution (PBS; in g/L): NaCl 8.0, Na₂HPO₄ 0.42, H₂O 0.77, KCl 0.20, KH₂PO₄ 0.19 (pH 7.2), longitudinally opened and fixed (paraformaldehyde 4% in PBS; 50 min; room temperature, RT). After two 15 min washing cycles with PBS-T (PBS with 0.3% of Triton X-100), each arterial segment was incubated with the primary antibodies against: nNOS, (mouse monoclonal anti-NOS1; 1:200 dilution, overnight), and GFAP (rabbit polyclonal anti-glial fibrillary acidic protein, 1:200 dilution, overnight, 4°C). After a PBS (4x15min) washout period, tissues were incubated with
Alexa 488 anti-mouse and Alexa 647 anti-rabbit fluorescent secondary antibodies (1:1000 dilution, 1h, RT). Negative controls were performed by omitting primary antibodies. After two PBS washing cycles, tissue preparations were mounted with antifading agent (vectashield mounting medium with DAPI, Vector Laboratories, UK), with the adventitial side facing up. Preparations were visualized with a Leica SP5 laser scanning confocal microscopy system (Leica Microsystems, Germany) fitted with an inverted microscope (x63 oil immersion lens). Stacks of 1-μm-thick serial optical images were captured from the entire adventitial layer, which was identified by the shape and orientation of the nuclei. Image acquisition was performed always under the same laser power, brightness and contrast conditions. Serial images from 3 different regions of the adventitia layer were acquired from each mesenteric and tail artery at 360 nm Ex/460 nm Em (for location of cell nuclei), at 488 nm Ex/525 nm Em (location of nNOS containing cells) and at 633 nm Ex/665 nm Em (location of Schwann cells) wavelengths. The resulting images were reconstructed separately for each wavelength with the Leica SP5 laser scanning confocal microscopy system (Leica Microsystems, Germany).

Data Analysis

Measurement of drug effects on electrically-evoked tritium overflow. Electrically-evoked tritium overflow from artery segments incubated with [3H]-noradrenaline has been shown to reflect action potential-evoked neuronal noradrenaline release and drug-induced changes in evoked tritium overflow are assumed to reflect changes in neuronal noradrenaline release. Effects of drugs added after S1 on electrically-evoked tritium overflow were evaluated as ratios of the overflow elicited by S2 and the overflow elicited by S1 (S2/S1). S2/S1 ratios obtained in individual experiments in which a test compound A was added after S1 were calculated as a percentage of the respective mean ratio in the appropriate control group (solvent instead of A) [25–27,34–36].

Laser Scanning Confocal Microscopy image quantification. Quantitative analysis of confocal z-stacks images was performed using an image analysis software (PAQI, CEMUP, Oporto, Portugal). Briefly, a sequential routine was designed and developed to analyze each fluorescent signal used. PAQI software measured the surface area and intensity of immunofluorescence of the antibody against neuronal NOS isoform, the surface area and intensity of immunofluorescence of the antibody against GFAP and determined the surface area of attachment of the antibodies anti-nNOS and anti-GFAP.

Statistics. Results are expressed as mean±s.e.m. and n denotes the number of animals used with triplicate tissue preparations. Differences of means were compared for significance using one-way ANOVA and the post-hoc Holm-Sidak’s multicomparisons test. A P value lower than 0.05, 0.01 or 0.001 was considered to denote statistically significant differences.

Results

The fractional rate of basal tritium outflow (b1), electrically-evoked tritium overflow (S1) and S2/S1 ratios of mesenteric and tail arteries are shown in Table 1 and Fig 1.

Basal outflow and electrically-evoked tritium overflow remained constant throughout the control experiments, with b b1 and S2/S1 values close to unity. Electrically-evoked tritium overflow (S1) was similar in mesenteric and tail arteries. However, in the presence of NO donors, DEA-NONOate (10 μM) or SNP (10 μM), opposite effects in the S2 electrically-evoked tritium overflow were observed: in mesenteric arteries, NO donors caused an inhibition whereas in tail arteries these compounds induced facilitation, as depicted in Fig 1.

In the mesenteric artery, inhibition of electrically-evoked tritium overflow induced by DEA/NONOate was abolished by the selective adenosine A1 receptors antagonist, DPCPX (20 nM),
and was not altered by the selective adenosine A2A receptors antagonist, SCH 58261 (20 nM), or by the adenosine kinase inhibitor, ITU (100 nM; Fig 2). In the tail artery, however, neither adenosine receptors antagonists (DPCPX and SCH 58261) nor the adenosine kinase inhibitor, ITU, affected facilitation of electrically-evoked tritium overflow elicited by NO. Adenosine receptor antagonists did not influence tritium overflow as depicted in Table 2.

In mesenteric artery, L-NAME (a non-selective NOS inhibitor) and Nω-Propyl-L-arginine hydrochloride (a selective nNOS inhibitor) facilitated electrically-evoked tritium overflow up to 21% and 35%, respectively (Fig 3). However, L-NIO dihydrochloride, a selective eNOS inhibitor, was devoid of effect. In tail artery, however, the effect elicited by NOS inhibitors on the electrically-evoked tritium overflow presented an opposite profile: L-NAME and L-NIO dihydrochloride inhibited electrically-evoked tritium overflow (in approximately 30%), an effect compatible with the facilitatory role of NO donors described above in this artery, whereas the nNOS inhibitor, failed to change tritium release (Fig 3).

Additional experiments were performed with endothelium removal (endothelium was mechanically removed from arteries with a stainless steel wire) in order to confirm the existence of the two NO sources: endothelial or neuronal. In fact, endothelium removal in tail artery reverted L-NAME and L-NIO dihydrochloride mediated effects on the electrically-evoked tritium overflow (S2/S1, % of appropriate control, were 97.16% ± 8.33; n = 6 and 109.56% ± 13.03; n = 5, for L-NAME and L-NIO dihydrochloride, respectively). Moreover, for mesenteric artery, endothelium removal did not modified L-NAME mediated effects when compared with results obtained in intact arteries (S2/S1, % of appropriate control, was 117.51% ± 2.67; n = 4, for L-NAME). Taking into consideration that L-NAME is a non-specific NOS inhibitor and have the ability to inhibit both endothelial and neuronal NOS and, since L-NAME data, in denuded and intact arteries, present the same effect on electrically-evoked tritium overflow, the putative involvement of endothelial NO in altering neurotransmission can be discarded.

Results indicate distinct NO modulatory roles in the two vessels in study which can be related with differences in the NO source. To confirm this later possibility, the immunoreactivity for nNOS, in the mesenteric and tail arteries, was studied (Fig 4A). We focused our attention to

Table 1. Basal tritium outflow (b1), electrically evoked tritium overflow (S1) and S2/S1 ratios from mesenteric and tail arteries.

|                | Basal Outflow (b1) (fractional rate of outflow; min⁻¹) | Evoked Overflow (S1) (% of tissue tritium content) | S2/S1       | n  |
|----------------|--------------------------------------------------------|---------------------------------------------------|-------------|----|
| **Mesenteric** |                                                        |                                                   |             |    |
| artery         |                                                        |                                                   |             |    |
| Solvent        | 0.070±0.008                                            | 0.229±0.037                                       | 0.980±0.048 | 6  |
| DEA-NONOate    | 0.068±0.008                                            | 0.227±0.037                                       | 0.808±0.063 | *  |
| **Tail**       |                                                        |                                                   |             |    |
| artery         |                                                        |                                                   |             |    |
| Solvent        | 0.077±0.003                                            | 0.185±0.015                                       | 1.027±0.081 | 6  |
| DEA-NONOate    | 0.075±0.009                                            | 0.193±0.015                                       | 1.266±0.067 | *  |

Tissue preparations of mesenteric and caudal arteries were pre-incubated with [³H]-noradrenaline for 40 min. After pre-incubation with [³H]-noradrenaline, tissues were superfused with [³H]-noradrenaline free medium containing desipramine (400 nM). Tissues were stimulated twice at 30-min intervals (S1-S2; 100 pulses, 5 Hz, 1 ms, 50 mA): b1 refers to the 5-min period immediately before S1. The electrically-evoked tritium overflow was calculated by subtracting the estimated basal outflow from total outflow observed during and in the 25-min period subsequent to S1 and expressed as a percentage of the tissue tritium content at the onset of stimulation. Values presented are means±SEM and n denotes the number of tissue preparations. Means were compared for significance using one-way ANOVA, followed by post-hoc Holm-Sidak’s multicomparisons t-test. Significant differences from the respective solvent: *P<0.050.

doi:10.1371/journal.pone.0129224.t001

Endothelial and Neuronal NO Influence on Sympathetic Neurotransmission
Fig 1. Panel A: time course of fractional tritium release from mesenteric and tail artery controls (filled circles) and from mesenteric and tail arteries with the NO donor, DEA-NONOate (open circles) taken from a typical experiment. Each line represents the outflow of tritium from a single superfusion chamber. After pre-incubation with [3H]-noradrenaline, tissues were superfused with [3H]-noradrenaline free medium containing desipramine (400 nM). Drugs were added immediately after S1 and kept until the end of the experiment. Tritium outflow (ordinates) is expressed as a percentage of the total radioactivity present in the tissue at the beginning of the collection period and was measured in samples collected every 5 min. Artery segments were stimulated twice (S1, S2) using 100 pulses/5Hz, 1 ms, 50 mA. Panel B: Influence of nitric oxide donors, SNP (10 μM) and DEA-NONOate (10 μM), on the modulation of electrically evoked tritium overflow in tail and mesenteric arteries. Arteries were electrically stimulated (S1-S2: 100 pulses, 5 Hz, 1 ms, 50 mA). Drugs were added immediately after S1 and kept until the end of the experiment. Ordinates: S2/S1 values obtained in individual tissue preparations, expressed as a percentage of the appropriate S2/S1 control value. Values are means ± s.e.m. from n = 4–6. Significant differences from solvent: *P<0.05 (one-way ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t-test).

doi:10.1371/journal.pone.0129224.g001
he vascular adventitia layer since our goal was to analyse the vascular sympathetic neurotransmission, an event that occurs in the sympathetic nerves spread in the adventitia layer. LSCM images from the adventitial layers, of both mesenteric and tail arteries, exhibited nNOS isoform immunoreactivities (Fig 4A), but quantitative analysis evidenced that the relative amount of nNOS immunoreactivity present in tail arteries is lower (up to 27% lower) than that exhibited in mesenteric arteries (Fig 4B). These results together with functional data (Fig 3) reveal and support a differential role of nNOS in the tail and mesenteric arteries.

We have previously demonstrated that sympathetic nerves are surrounded by Schwann cells (anti-GFAP-immunoreactivity) [25]. The putative presence of nNOS isoform immunoreactivities (Fig 4A), but quantitative analysis evidenced that the relative amount of nNOS immunoreactivity present in tail arteries is lower (up to 27% lower) than that exhibited in mesenteric arteries (Fig 4B). These results together with functional data (Fig 3) reveal and support a differential role of nNOS in the tail and mesenteric arteries.

Endothelial and Neuronal NO Influence on Sympathetic Neurotransmission

Fig 2. Influence of the adenosine kinase inhibitor (ITU), the adenosine A₁ receptors antagonist (DPCPX) and the adenosine A₂A receptors antagonist (SCH 58261) in the nitric oxide donor DEA-NONOate (10 μM) induced modulation of electrically evoked tritium overflow, in mesenteric and tail arteries. Arteries were electrically stimulated (S₁, S₂: 100 pulses, 5 Hz, 1 ms, 50 mA). Drugs were added immediately after S₁ and kept until the end of the experiment. Ordinates: S₂/S₁ values obtained in individual tissue preparations, expressed as a percentage of the appropriate S₂/S₁ control value. Values are mean±SEM from n = 4–6. Significant differences from the appropriate control: *P<0.05; **P<0.01 and from DEA-NONOate: *P<0.001 (one-way ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t-test).
was also observed in cells present in adventitia, other than Schwann cells, in both mesenteric and tail artery images (depicted by open arrows): 62.5% in mesenteric and 88% in tail artery images (Fig 4, A e D).

Taken together, these morphological data support the occurrence of differences on nNOS isoform presence in mesenteric and tail arteries and reveal an important role for Schwann cells as an NO source, in mesenteric arteries.

Discussion

The present results demonstrate that the NO modulatory role on sympathetic neurotransmission and the different contribution of NO from neuronal and endothelial sources are dependent on the vascular bed. In mesenteric arteries nNOS, mainly localized in Schwann cells, seems to be the main source of NO influencing perivascular sympathetic neurotransmission, while in tail arteries the endothelium seems to play the most relevant role. Intracellular signaling cascades and adenosine receptors involved in the two vessels are also different.

In mesenteric arteries we found that an increase in NO availability, via addition of NO donors, reduced noradrenaline release in the synaptic cleft. As a consequence, a reduction in the vasoconstrictor effect mediated by activation of smooth muscle $\alpha_1$-adrenoceptors will occur. These results are in line with previous studies that reported an altered vascular reactivity induced by NO at the sympathetic neuroeffector junction, ascribed to the deactivation of the vasoconstrictor, noradrenaline in the rat mesenteric bed [37]. However, in tail arteries NO mediated an opposite effect: an increase of noradrenaline release levels. Taken together, these data seem to indicate a different neuromodulatory role of NO in the neurovascular junction of mesenteric and tail arteries, most likely, due to the activation of different pathways.

In addition to the well characterized classical mechanism by which NO mediates its effects, via sGC-cGMP-PKG [38–41], results obtained in the current study, suggest that, in mesenteric arteries, inhibition of sympathetic transmission by NO seems to activate an alternative signaling pathway and/or the involvement of different NOS isoforms. Increasing evidence suggest that NO may also signal through a cGMP independent pathway: NO inhibits the Krebs cycle

|                | S$_2$/S$_1$ (% of solvent) | n |
|----------------|---------------------------|---|
| **Mesenteric artery** |                          |   |
| DPCPX          | 101.41 ± 2.67             | 4 |
| SCH 58261      | 106.04 ± 3.08             | 8 |
| **Tail artery** |                          |   |
| DPCPX          | 99.46 ± 3.81              | 6 |
| SCH 58261      | 98.70 ± 7.99              | 10|

Tissue preparations of mesenteric and caudal arteries were pre-incubated with $[^3]$H]-noradrenaline for 40 min. After pre-incubation with $[^3]$H]-noradrenaline, tissues were superfused with $[^3]$H]-noradrenaline free medium containing desipramine (400 nM). Tissues were stimulated twice at 30-min intervals (S$_1$-S$_2$; 100 pulses, 5 Hz, 1 ms, 50 mA). The electrically-evoked tritium overflow was calculated by subtracting the estimated basal outflow from total outflow observed during and in the 25-min period subsequent to S$_1$ and expressed as a percentage of the tissue tritium content at the onset of stimulation. Values presented are means ± SEM and n denotes the number of tissue preparations. Means were compared for significance using one-way ANOVA, followed by post-hoc Holm-Sidak’s multicomparisons t-test. No significant differences from the respective solvent were observed.

doi:10.1371/journal.pone.0129224.t002
and inhibits complex I and IV of the mitochondrial respiratory chain [43,44] compromising the mitochondrial function in neurons [45] leading to ATP hydrolysis and subsequent accumulation of adenosine [46,47] that, in turn, can signal through activation of high affinity adenosine receptors (A1 and A2A subtypes) or low affinity adenosine receptors (A2B and A3 subtypes). Indeed, the inhibition of noradrenaline release induced by NO seems to be mediated by activation (by adenosine) of the adenosine A1 receptors subtype since the inhibition of noradrenaline release mediated by NO donors was prevented by the adenosine A1 receptors antagonist (DPCPX) but was not altered by the adenosine A2A receptors antagonist (SCH 58261).

Similar NO-mediated mechanisms have also been described to occur in several central nervous system tissues, such as the hippocampus [48–50] or the nucleus tractus solitarius [51].

It is well established that adenosine availability in the extracellular space may depend on nucleoside transporters and on the activity rate of adenosine kinase [52–54], as well as on the neuronal exocytotic ATP release [55–57]. In mesenteric arteries, we have demonstrated previously that exocytosis (induced by electrical field stimulation) did not modify the amount of adenosine available at the extracellular space [25]. Therefore, adenosine accumulation in the present...
conditions could result from the transport of adenosine via nucleoside transporters or from adenosine kinase inhibition (adenosine kinase is inhibited by adenosine itself). The first hypothesis was previously demonstrated by our group [25] whereas the later possibility was ruled out in the present work, since ITU (an adenosine kinase inhibitor) was devoid of effect upon the NO-induced (with NO donors) inhibition of noradrenaline release.

On the other hand, in mesenteric arteries, selective NOS isoform inhibitors also differentially influenced noradrenaline release: nNOS inhibitors increased noradrenaline release, an effect in agreement with results from previous studies in rat [7,9,10,37,58] and rabbit [59] which described NO as a mediator able to reduce noradrenaline release. Instead, the eNOS inhibitor showed no significant effect. Moreover, the non-selective NOS inhibitor, which inhibits both isoforms (nNOS and eNOS), modified noradrenaline release in mesenteric arteries in a similar
way to that observed for the nNOS inhibitor. These results suggest that, in mesenteric arteries, only nNOS contributes to NO generation that, ultimately, will lead to the decrease in noradrenaline release. NO generation can be ascribed to both oxygenase and reductase domains of NO synthase. L-NAME, described to be unable to modify the activity of the reductase domain [60], did not completely revert the endogenous NO mediated effects on noradrenaline release whereas the nNOS inhibitor completely reverted it.

Similar experiments were carried out in the tail artery but, in this vessel, the NO-mediated effects (increase of noradrenaline release) are due to NO generated only by the eNOS isoform. The selective eNOS inhibitor and of the non-selective NOS inhibitor, caused a decrease in noradrenaline release but the selective nNOS inhibitor failed to modify noradrenaline release in tail arteries. Therefore, NO generated by eNOS isoform, in tail arteries, increases noradrenaline release, as previously suggested to occur in mice kidneys, where the presynaptic active NO seemed to be exclusively produced by the eNOS isoform [61].

It is accepted that NOS produces NO as result of the oxygenase and reductase domains activities which are responsible for the conversion of L-arginine to L-citrulline plus NO and of the conversion of nitrites to NO, respectively [62]. This later reaction was previously shown to be not affected by L-NAME [60]. In tail artery, the inhibition promoted by eNOS inhibitors (L-NAME and L-NIO dihydrochloride) completely reverted the effects mediated by NO on sympathetic transmission (Fig 3). These results indicate that, in tail arteries, the major contribution for NO production seems to be ascribed to the eNOS oxygenase domain.

In tail arteries, the enhancement of noradrenaline release (induced by NO) is, most likely, due to the activation of signaling cascades different from those observed in mesenteric arteries. In fact, data showed that the effects mediated by NO donors in sympathetic transmission were not altered by the adenosine receptors antagonists studied (DPCPX and SCH 58261), nor the adenosine kinase inhibitor, (ITU). These data do not support the occurrence of an adenosine accumulation evoked by NO mediated effects on mitochondrial respiration [47], which are known to require higher NO amounts [49]. This can be explained by a residual activity of the eNOS reductase domain in tail arteries. Taken together, these data strongly suggest that this is not the predominant pathway by which NO mediate its effects, in tail artery. Classically, it is accepted that NO mediate its effects by activating guanylyl cyclase to generate cGMP. cGMP and cGMP-dependent protein kinase are capable of modulating membrane potential and ion channels [19,63]. Moreover, a cGMP-mediated enhancement of Ca\(^{2+}\) channel currents in sympathetic neurons has also been reported [64]. It is, therefore, possible that the facilitation of noradrenaline release induced by NO can be ascribed to cGMP-mediated changes in activated voltage-dependent Ca\(^{2+}\) channels [19]. Moreover, data obtained in denuded arteries constitute an additional support for hypothesis of the existence of distinct NO sources (confirmed by the selective NOS inhibitors mediated effects) that will be responsible for activation of distinct pathways on sympathetic neurotransmission in rat tail and mesenteric arteries.

Confocal microscopy studies showed the presence of nNOS isoform in the adventitia layer of both mesenteric and tail arteries. These data agree well with those from a study that described the presence of nNOS isoform in mesenteric arteries [58]. Confocal microscopy data are in agreement with the absence of nNOS effect on sympathetic neurotransmission found in the tail artery, since a considerably lower amount of this isoform (27% of reduction) was observed in tail arteries, comparatively to mesenteric arteries. Our data also show, for the first time, that nNOS is distributed in two main locations: one expressed in Schwann cells and another, more abundant in other cells, about 63% and 88% in the adventitia of mesenteric and tail arteries, respectively. Therefore, it is conceivable that nNOS, expressed in Schwann cells, might be producing NO that would be causing the inhibition of noradrenaline release from sympathetic nerves. Our findings are in agreement with this possibility, since the relative
amount of nNOS expressed in Schwann cells in the two arteries is markedly different: 50% in mesenteric versus 4% in tail arteries. These data also correlates with the functional results obtained, showing a lack of neuromodulatory role of nNOS in tail arteries whereas in mesenteric arteries nNOS contributed to reduce noradrenaline release up to 33% (Fig 3).

In summary, the present results suggest that the NO modulatory role on sympathetic neurotransmission differs in the mesenteric and tail arteries depending on the NO source, eNOS and/or nNOS, involved in its production. Moreover, the signalling cascades induced by the NO available in each artery are also distinct in the two vessels: in mesenteric artery, NO leads to adenosine accumulation which activates adenosine A1 receptors causing an inhibition of sympathetic transmission whereas, in tail arteries, this via is not the dominant one, and instead, the activation of guanylyl cyclase-cGMP-cGMP-dependent protein kinase- voltage-dependent Ca2+ channels is most likely to occur. Additionally, this work revealed that the location of the nNOS isoform may also be crucial to the differences in the neuromodulation exerted by NO in the two arteries studied, since the nNOS isoform present in Schwann cells seem to be the main source of NO to perivascular sympathetic nerves.

Acknowledgments
This work was supported by FEDER through Program of Operational Competitiveness Factors —COMPETE and by National Funds through Foundation for Science and Technology (FCT): Grant Nº. PEst C/EQB/LA0006/2011. JBS thank FCT for her PhD grant (SFRH/BD//2009).

Author Contributions
Conceived and designed the experiments: JBS CD.Performed the experiments: JBS MSVR. Analyzed the data: JBS CD. Contributed reagents/materials/analysis tools: SMA MCG CD. Wrote the paper: JBS SMA PF CD.

References
1. Alderton WK, Cooper CE, Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593–615. PMID: 11463332
2. Domenico R (2004) Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies. Curr Pharm Des 10: 1667–1676. PMID: 15134564
3. Andrew PJ, Mayer B (1999) Enzymatic function of nitric oxide synthases. Cardiovasc Res 43: 521–531. PMID: 10690324
4. Michel T, Vanhoutte PM (2010) Cellular signaling and NO production. Pflugers Arch 459: 807–816. doi: 10.1007/s00424-009-0765-9 PMID: 20082095
5. del Campo L, Ferrer M, Balfagon G (2009) Hypertension alters the function of nitricergic and sensory innervation in mesenteric arteries from female rats. J Hypertens 27: 791–799. doi: 10.1097/HJH.0b013e32832531e6 PMID: 19516178
6. Xavier FE, Blanco-Rivero J, Avendano MS, Sastre E, Yela R, et al. (2011) Aldosterone alters the participation of endothelial factors in noradrenaline vasoconstriction differently in resistance arteries from normotensive and hypertensive rats. Eur J Pharmacol 654: 280–288. doi: 10.1016/j.ejphar.2011.01.007 PMID: 21262224
7. Blanco-Rivero J, Sastre E, Caracuel L, Granado M, Balfagon G (2013) Breast feeding increases vasoconstriction induced by electrical field stimulation in rat mesenteric artery. Role of neuronal nitric oxide and ATP. PLoS One 8: e53802. doi: 10.1371/journal.pone.0053802 PMID: 23342008
8. Blanco-Rivero J, Roque FR, Sastre E, Caracuel L, Coute GK, et al. (2013) Aerobic exercise training increases neuronal nitric oxide release and bioavailability and decreases noradrenaline release in mesenteric artery from spontaneously hypertensive rats. J Hypertens 31: 916–926. doi: 10.1097/HJH.0b013e32835f749c PMID: 23429863
9. Kolo LL, Westfall TC, Macarthur H (2004) Modulation of neurotransmitter release by NO is altered in mesenteric arterial bed of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 287: H1842–H1847. PMID: 15205164
10. Macarthur H, Wilken GH, Westfall TC, Kolo LL (2011) Neuronal and non-neuronal modulation of sympathetic neurovascular transmission. Acta Physiol (Oxf) 203: 37–45. doi: 10.1111/j.1748-1716.2010.02242.x PMID: 21362154

11. Prast H, Philippu A (2001) Nitric oxide as modulator of neuronal function. Prog Neurobiol 64: 51–68. PMID: 11250062

12. Addicks K, Bloch W, Feilisch M (1994) Nitric oxide modulates sympathetic neurotransmission at the prejunctional level. Microsc Res Tech 29: 161–168. PMID: 7529070

13. Yu M, McAndrew RP, Al-Saghir R, Maier KG, Medhora M, et al. (2002) Nitric oxide contributes to 20-HETE-induced relaxation of pulmonary arteries. J Appl Physiol (1985) 93: 1391–1399. PMID: 12235040

14. Brassai A, Mako K, Domjanschitz L, Sperlagh B (2002) Lack of prejunctional modulation of noradrenaline release by endogenous nitric oxide in guinea pig pulmonary artery. Neurochem Int 41: 279–283. PMID: 12106779

15. Vaz-da-Silva MJ, Guimaraes S, Moura D (1995) Adenosine and the endothelium-dependent modulation of 3H-noradrenaline release in the canine pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 352: 640–645. PMID: 9057376

16. Schwarz P, Diem R, Dun NJ, Forstermann U (1995) Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 77: 841–848. PMID: 7554131

17. Yoshida M, Akaike T, Inadome A, Takahashi W, Seshita H, et al. (1998) The possible effect of nitric oxide on relaxation and noradrenaline release in the isolated rabbit urethra. Eur J Pharmacol 357: 213–219. PMID: 9797039

18. Mohan RM, Paterson DJ (2000) Activation of sulphonylurea-sensitive channels and the NO-cGMP pathway decreases the heart rate response to sympathetic nerve stimulation. Cardiovasc Res 47: 81–89. PMID: 10869533

19. Martire M, Altobelli D, Cannizzaro C, Preziosi P (1998) Effects of nitric oxide donors on basal and K+-evoked release of [3H]noradrenaline from rat cerebral cortex synaptosomes. Eur J Pharmacol 350: 345–351. PMID: 9696426

20. Lonart G, Johnson KM (1995) Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. I. The role of glutamate. J Pharmacol Exp Ther 275: 7–13. PMID: 7562597

21. Lonart G, Johnson KM (1995) Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. II. The role of calcium, reverse norepinephrine transport and cyclic 3’,5’-guanosine monophosphate. J Pharmacol Exp Ther 275: 14–22. PMID: 7562542

22. Lu Y, Chung HJ, Li Y, Rosenberg PA (2003) NMDA receptor-mediated extracellular adenosine accumulation in rat forebrain neurons in culture is associated with inhibition of adenosine kinase. Eur J Neurosci 17: 1213–1222. PMID: 12670309

23. Rocha-Pereira C, Sousa JB, Vieira-Rocha MS, Fresco P, Goncalves J, et al. (2013) Differential inhibition of noradrenaline release mediated by inhibitory A(1)-adenosine receptors in the mesenteric vein and artery from normotensive and hypertensive rats. Neurochem Int 62: 399–405. doi: 10.1016/j.neuint.2013.02.010 PMID: 23416044

24. Rocha-Pereira C, Arribas SM, Fresco P, Gonzalez MC, Goncalves J, et al. (2013) Impaired inhibitory function of presynaptic A1-adenosine receptors in SHR mesenteric arteries. J Pharmacol Sci 122: 59–70. PMID: 23782593

25. Sousa JB, Vieira-Rocha MS, Sa C, Ferreirinha F, Correia-de-Sa P, et al. (2014) Lack of endogenous adenosine tonus on sympathetic neurotransmission in spontaneously hypertensive rat mesenteric artery. PLoS One 9: e105540. doi: 10.1371/journal.pone.0105540 PMID: 25158061

26. Sousa JB, Fresco P, Diniz C (2015) Endothelial dysfunction impairs vascular neurotransmission in tail arteries. Neurochem Int 80: 7–13. doi: 10.1016/j.neuint.2014.11.001 PMID: 25447785

27. Diniz C, Fresco P, Leal S, Goncalves J (2004) Adenosine receptors involved in modulation of noradrenaline release in isolated rat tail artery. Eur J Pharmacol 504: 17–25. PMID: 15507216

28. Fresco P, Diniz C, Goncalves J (2004) Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylyl cyclase pathways in rat tail artery. Cardiovasc Res 63: 739–746. PMID: 15306230

29. Fresco P, Diniz C, Queiroz G, Goncalves J (2002) Release inhibitory receptors activation favours the A2A-adenosine receptor-mediated facilitation of noradrenaline release in isolated rat tail artery. Br J Pharmacol 136: 230–236. PMID: 12010771

30. Fresco P, Oliveira JM, Kunc F, Soares AS, Rocha-Pereira C, et al. (2007) A2A adenosine-receptor-mediated facilitation of noradrenaline release in rat tail artery involves protein kinase C activation and beta-gamma subunits formed after alpha2-adrenoceptor activation. Neurochem Int 51: 47–56. PMID: 17493708
31. Tripovic D, McLachlan EM, Brock JA (2013) Removal of half the sympathetic innervation does not reduce vasoconstrictor responses in rat tail artery. J Physiol 591: 2867–2884. doi: 10.1113/jphysiol.2012.250365 PMID: 23551946

32. Shinozuka K, Mizuno H, Nakamura K, Kunitomo M (2002) Purinergic modulation of vascular sympathetic neurotransmission. Jpn J Pharmacol 88: 19–25. PMID: 11855674

33. Johnson CD (2010) A demonstration of sympathetic cotransmission. Adv Physiol Educ 34: 217–221. doi: 10.1152/advan.00070.2010 PMID: 21098390

34. von Kugelgen I, Stoffel D, Starke K (1995) P2-purinoceptor-mediated inhibition of noradrenaline release in rat atria. Br J Pharmacol 115: 247–254. PMID: 7670726

35. Talaia C, Morato M, Quintas C, Goncalves J, Queiroz G (2011) Functional crosstalk of prejunctional receptors on the modulation of noradrenaline release in mesenteric vessels: A differential study of artery and vein. Eur J Pharmacol 652: 33–39. doi: 10.1016/j.ejphar.2010.10.075 PMID: 2114976

36. Queiroz G, Quintas C, Talaia C, Goncalves J (2004) Coupling to protein kinases A and C of adenosine A2B receptors involved in the facilitation of noradrenaline release in the prostatic portion of rat vas deferens. Neuropharmacology 47: 216–224. PMID: 15223300

37. Kolo LL, Westfall TC, Macarthur H (2004) Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed. Am J Physiol Heart Circ Physiol 286: H296–303. PMID: 14684362

38. Denninger JW, Marletta MA (1999) Guanylate cyclase and the cGMP signaling pathway. Biochim Biophys Acta 1411: 334–350. PMID: 10320667

39. Domek-Lopinska K, Strosznajder JB (2005) Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol 56 Suppl 2: 15–34. PMID: 16077188

40. Pilz RB, Broderick KE (2005) Role of cyclic GMP in gene regulation. Front Biosci 10: 1239–1268. PMID: 15769622

41. Li D, Wang L, Lee CW, Dawson TA, Paterson DJ (2007) Noradrenergic cell specific gene transfer with neuronal nitric oxide synthase reduces cardiac sympathetic neurotransmission in hypertensive rats. Hypertension 50: 69–74. PMID: 17515453

42. Castro AF, Amorena C, Muller A, Ottaviano G, Tellez-Inon MT, et al. (1998) Extracellular ATP and bradykinin increase cGMP in vascular endothelial cells via activation of PKC. Am J Physiol 275: C113–119. PMID: 9688941

43. Brown GC, Bai-Price A (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27: 325–355. PMID: 12845153

44. Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, et al. (2005) Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 65: 803–812. PMID: 15721860

45. Broson JR, Schumacker PT, Zhang H (1999) Nitric oxide acutely inhibits neuronal energy production. The Committees on Neurobiology and Cell Physiology. J Neurosci 19: 147–158. PMID: 9870946

46. Rosenberg PA, Li Y, Le M, Zhang Y (2000) Nitric oxide-stimulated increase in extracellular adenosine accumulation in rat forebrain neurons in culture is associated with ATP hydrolysis and inhibition of adenosine kinase activity. J Neurosci 20: 6294–6301. PMID: 10934281

47. Bon CL, Garthwaite J (2001) Nitric oxide-induced potentiation of CA1 hippocampal synaptic transmission during baseline stimulation is strictly frequency-dependent. Neuropharmacology 40: 501–507. PMID: 11249955

48. Fragata IR, Ribeiro JA, Sebastiao AM (2006) Nitric oxide mediates interactions between GABAA receptors and adenosine A1 receptors in the rat hippocampus. Eur J Pharmacol 543: 32–39. PMID: 16831416

49. Arrigoni E, Rosenberg PA (2006) Nitric oxide-induced adenosine inhibition of hippocampal synaptic transmission depends on adenosine kinase inhibition and is cyclic GMP independent. Eur J Neurosci 24: 2471–2480. PMID: 17100836

50. Song MS, Shin KA, Kang JS, Lee CH, Shin IC, et al. (2002) The involvement of nitric oxide on the adenosine A(2) receptor-induced cardiovascular inhibitory responses in the posterior hypothalamus of rats. Neurosci Lett 326: 41–46. PMID: 12052534

51. Lo WC, Jan CR, Wu SN, Tseng C (1998) Cardiovascular effects of nitric oxide and adenosine in the nucleus tractus solitarii of rats. Hypertension 32: 1034–1038. PMID: 9856969

52. Sinclair CJ, Powell AE, Xiong W, LaRiviere CG, Baldwin SA, et al. (2001) Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors. Br J Pharmacol 134: 1037–1044. PMID: 11682452
53. Lovatt D, Xu Q, Liu W, Takano T, Smith NA, et al. (2012) Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci U S A 109: 6265–6270. doi: 10.1073/pnas.1120997109 PMID: 22421436

54. Boison D (2013) Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev 65: 906–943. doi: 10.1124/pr.112.006361 PMID: 23592612

55. White TD, MacDonald WF (1990) Neural release of ATP and adenosine. Ann N Y Acad Sci 603: 287–298; discussion 298–289. PMID: 2291528

56. Jo YH, Schlichter R (1999) Synaptic corelease of ATP and GABA in cultured spinal neurons. Nat Neurosci 2: 241–245. PMID: 10195216

57. Pankratov Y, Lalo U, Verkhratsky A, North RA (2007) Quantal release of ATP in mouse cortex. J Gen Physiol 129: 257–265. PMID: 17325196

58. Koyama T, Hatanaka Y, Jin X, Yokomizo A, Fujiwara H, et al. (2010) Altered function of nitrergic nerves inhibiting sympathetic neurotransmission in mesenteric vascular beds of renovascular hypertensive rats. Hypertens Res 33: 485–491. doi: 10.1038/hr.2010.48 PMID: 20379183

59. Gonzalez C, Martin C, Hamel E, Galea E, Gomez B, et al. (1990) Endothelial cells inhibit the vascular response to adrenergic nerve stimulation by a receptor-mediated mechanism. Can J Physiol Pharmacol 68: 104–109. PMID: 2328438

60. Webb AJ, Milsom AB, Rathod KS, Chu WL, Qureshi S, et al. (2008) Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res 103: 957–964. doi: 10.1161/CIRCRESAHA.108.175810 PMID: 1818408

61. Stegbauer J, Kuczka Y, Vonend O, Quack I, Sellin L, et al. (2008) Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release. Am J Physiol Regul Integr Comp Physiol 294: R421–428. PMID: 18046021

62. Gautier C, van Faassen E, Mikula I, Martasek P, Slama-Schwok A (2006) Endothelial nitric oxide synthase reduces nitrite anions to NO under anoxia. Biochem Biophys Res Commun 341: 816–821. PMID: 16442076

63. Butt E, Geiger J, Jarchau T, Lohmann SM, Walter U (1993) The cGMP-dependent protein kinase—gene, protein, and function. Neurochem Res 18: 27–42. PMID: 8385276

64. Chen C, Schofield GG (1995) Nitric oxide donors enhanced Ca2+ currents and blocked noradrenaline-induced Ca2+ current inhibition in rat sympathetic neurons. J Physiol 482 (Pt 3): 521–531. PMID: 7738846